UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of small business issuer as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
Commission File No.
(Address of Principal Executive Offices)
(
(Issuer’s telephone number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| None |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
| 1 |
Item 8.01 Other Events.
On September 19, 2022 Regen Biopharma, Inc. (the “Company”) issued a press release titled “Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy” the text of which is attached to this Current Report on Form 8-K as Exhibit 99.1. The purpose of this Current Report on Form 8-K is to further clarify the information contained within the aforementioned press release.
The invention which is the subject of the provisional patent application which is the subject of the press release attached to this Current Report as Exhibit 99.1 is intended at expanding the use of the Company’s patented technology to inhibit a T cell checkpoint called NR2F6. The Company has multiple patented and patent-pending approaches to treating cancer directly or via immunotherapy. Immunotherapy drugs are ones which manipulate the body’s own immune system to clear it of cancer. By releasing the natural brake in T cells, the Company expects that its drugs will allow a patient’s immune cells to be highly activated. The Company is pursuing several such approaches within this very competitive field of cancer treatment. Therefore, the Company has a patent portfolio built around cellular therapies, small molecules, aptamers and RNA vaccines.
Item 9.01 Exhibits.
| Exhibit No. | Description of Exhibit | |
| 99.1 | Press Release |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| REGEN BIOPHARMA, INC. | |
|
Dated: September 20, 2022 |
By: /s/ David Koos |
| 3 |
Exhibit 99.1
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy
Company Combines Existing NR2F6 and Survivin Gene Silencing Findings with Second Generation Checkpoint Inhibitor Approach
San Diego, September 19, 2022: Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP) announced today filing of a provisional patent application with the USPTO entitled “Dual Checkpoint Inhibitor Aptamer Based Therapeutics”. The application covers novel compositions of matter capable of acting as conventional checkpoint inhibitor drugs while simultaneously silencing genes which regulate T cells and cancer cells such as NR2F6 and Survivin. The Company believes that this platform technology is the first combination of an immunotherapy and a gene silencing agent in a single drug.
Aptamers are short DNA or RNA sequences which can function as antibodies – they recognize specific proteins and bind to them. This new technology takes advantage of the fact that the Company can put its proprietary RNA or DNA sequences which code for inhibitory RNAs on one end of an aptamer while using the other end of the aptamer to bind to, and thus inhibit, a traditional immune checkpoint such as PD-1. Once the aptamer is internalized into the cell, the proprietary DNA or RNA sequence is converted to an inhibitory RNA which targets other genes involved in T cell function or cancer growth leading to a two-pronged approach to T cell activation or cancer-killing.
“Our Company has been working on RNA therapeutics for several years, including being granted a U.S. patent for survivin-based RNA vaccines, as well as gene silencing of NR2F6,” said Dr. David Koos, CEO and Chairman of the Company. “We believe the merger of this technology with checkpoint inhibitors, and the resulting platform technology, will result in development of numerous potent therapeutic candidates.”
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. CONTACT INFORMATION Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fa